Panelists discuss how the introduction of bispecific antibodies is transforming the treatment landscape for relapsed/refractory multiple myeloma, addressing unmet needs and improving patient outcomes through innovative combination strategies and sequencing approaches.
EP. 1: Current Landscape of Relapsed/ Refractory Multiple Myeloma
October 18th 2024Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes.